Member Info for grizzlyb

If they can achieve an RP update in mid October, preceded a week or so before by announcement of Oxford commencement, and a week or so after with announcement of a with a new CTX partner, oh and some exosome data a few weeks after that...then we might just get funding at a reasonable rate. Don't mess it up for us, COVID.

You're all tenuous links and no substance. Not a single valid post.

Stroke therapy is the potential blockbuster, partners to move that programme forward will give the biggest boost imo. Hopefully AGM discussion will give further detail around recent discussions with potential partners.

It's this one (which may be what you've already seen):
https://www.edisongroup.com/publication/exploiting-the-potential-of-cell-therapy/27598

Absolutely agree, it does say £170 mil., that's more like it.

Just seen their Outlook document too, which has far more info than the 6 lines I read this morning.

Until Oxford is listed as a study location on the clinical trials database, I'm not going to get excited about dosing restarting.

Additionally, until today, Edison (to whom ReNeuron pay a fee of approximately £50k/annum) said they expected dosing to commence in Q4, and they weren't prepared to give a valuation.

As of today, they are saying the 2 million cell dosing 'could start this autumn.' And they have revised their valuation to £107 mil. down from £170 mil. And £197 mil. in February this year.

My expectation is that they will update on RP with, hopefully, positive results. Then enter NASDAQ with a capital raise on the back of those results. If they're pinning hopes on an exosome deal we're screwed. Wage bill is what, £4.5 mil/year? Staff will also want clarity on funding asap.

Further, for anybody at a loose end:

https://worldwide.espacenet.com/patent/search/family/060326655/publication/WO2019069093A1?q=reneuron

Found this screenshot on my work PC yesterday which reminded me why I'm excited about exosomes.

https://ibb.co/FhDN4TJ

My problem with Olav isn't his salary, it's that I can't recall anything he's done to add value. He must have done something, but it isn't visible. Meanwhile, our valuation is 1/3 of the value he joined at.

See my comment from yesterday at 13:39 :)

ExoKRAS and ExoBDNF are very exciting. But will in vitro results need to be peer reviewed before we gain financially from them? That's a long process.

Clivealive, I can't get too excited about the AGM when RP patient recruitment is still on hold and the UK trial hasn't commenced due to COVID.

Fortunately profitability isn't needed for a good valuation. Unfortunately, ReNeuron struggle to translate their technology into a good valuation.

Take cash out of the equation and the tech is valued at less than £30 million, which is unfortunate as they've spent far more than that to get to this stage.

Presumably he left as he founded Glialign amd has had a fair few shared granted over the years, so he's not all out.

CEO pay is certainly high, but that's one of the benefits of being a CEO :)

Shares investor evening was essentially the same as prelims presentation.

ExoKRAS and ExoBDNF are looking exciting. Previous lab work showed rapid obliteration of glioblastoma using ReNeuron's exosomes, very pleased to see work has continued in the background.

Am I correct in saying Evox and others have completed pre-clinical exosome testing for various indications, but are not yet in the clinic, whereas ReNeuron haven't completed pre-clinical, but our exosomes have essentially been tested, from a safety perspective, in the clinic via. the CTX stroke studies?

Indeed. And Nightstar's Prof Maclaren is on ReNeuron's scientific advisory board.

"The main point is perhaps that the whole hRPC story has now been validated by a decent-sized PH2b study."

That's a really valid point.

ReNeuron's current valuation: £37,000,000.

I was going to give essentially the same summary, onceaday.

Interesting that their sham and 3 million cell results were so close, for the sub-population also.

Importantly, from a cell availability and transportation point of view, jCell is a fresh preparation, whereas ReNeuron have cryopreservation of their hRPCs sorted.

Would it be better to issue new shares now to see PISCES III through to the end? Imagine trying to do that if the hRPC programme fails! Data = partnerships, pausing the programme does not.

Current price isn't a new low, we moved quite quickly from circa £0.60 to over £3.00 last year. But we also had more cash and a new deal with Fosun. My expectations for CTX are currently very low. This time last year they were very high.